Blisibimod Seen to Lower Urine Protein Levels in Patients with Renal Involvement in Phase 3 Trial

Results of a Phase 3 clinical trial of blisibimod, by Anthera Pharmaceuticals, found that treatment significantly reduces proteinuria — excess proteins in the urine — in patients with systemic lupus erythematous (SLE). Like many B-cell mediated autoimmune diseases, lupus is associated with elevated levels of B-cell activating factor (BAFF). Blisibimod is…

6 Common Symptoms of Lupus Nephritis

Lupus is an autoimmune disease that can attack any part of the body, including internal organs. The kidneys are commonly affected in lupus patients and can lead to the development of lupus nephritis. We’ve put together a list of five of the most common symptoms of lupus nephritis using information…